Anacor Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference Piper Jaffray Healthcare Conference 2012 Business Wire PALO ALTO, Calif. -- November 13, 2012 Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry, the company’s Chief Executive Officer, will be participating in the Piper Jaffray 24^th Annual Healthcare Conference on Wednesday, November 28, 2012 at 11:30 a.m. ET in New York, New York. The event will be webcast live and may be accessed under “Events and Presentations” on the Investors page of Anacor’s website at www.anacor.com. A replay will also be available for three months following the presentation. About Anacor Pharmaceuticals Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered seven compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds — tavaborole, a topical antifungal for the treatment of onychomycosis, and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis. In addition to its two lead programs, Anacor has discovered three other clinical product candidates — AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly known as GSK2251052, or GSK‘052), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKlineLLC, or GSK. GSK will be returning all rights to the compound to us and we are considering our options for further development, if any, of this compound. We have discovered two other compounds that we have out-licensed for further development — AN8194, a compound for the treatment of an animal health indication that is licensed to Eli Lilly and Company, or Lilly, and AN5568, also referred to as SCYX-7158, for human African trypanosomiasis (HAT, or sleeping sickness), which is licensed to Drugs for Neglected Diseases initiative, or DNDi. We also have a pipeline of other internally discovered topical and systemic boron-based compounds in development. For more information, visit http://www.anacor.com. Contact: Anacor Pharmaceuticals Director, Investor Relations and Corporate Communications DeDe Sheel, 650-543-7575
Anacor Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
Press spacebar to pause and continue. Press esc to stop.